<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03334851</url>
  </required_header>
  <id_info>
    <org_study_id>C1131001</org_study_id>
    <secondary_id>2017-003077-34</secondary_id>
    <nct_id>NCT03334851</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability Study Of PF-06835375 In Subjects With Seropositive Systemic Lupus Erythematosus Or Rheumatoid Arthritis</brief_title>
  <official_title>A Phase 1, Randomized, Multi-center, Double-blind, Sponsor Open, Placebo-controlled, Single And Multiple Dose-escalation Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-06835375 In Subjects With Seropositive Systemic Lupus Erythematosus Or Rheumatoid Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1 single and multiple dose escalation study to evaluate the safety,
      tolerability, pharmacokinetics, and pharmacodynamics of PF-06835375 in subjects with
      seropositive SLE or RA. The design is double-blind, sponsor open and placebo controlled. This
      study will include two parts: Part A and Part B. Part A will consist of single ascending dose
      cohorts, Part B of multiple ascending dose cohorts. This study will enroll up to a total of
      approximately 112 subjects at approximately 10 sites.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 17, 2017</start_date>
  <completion_date type="Anticipated">November 22, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 22, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with adverse events (AEs) by seriousness and relationship to treatment</measure>
    <time_frame>Day 1 through approximately Day 112</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with change from baseline in labboratory test results</measure>
    <time_frame>Day 1 through approximately Day 112</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with clinically relevant changes from baseline in ECG parameters</measure>
    <time_frame>Day 1 through approximately Day 112</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with infections</measure>
    <time_frame>Day 1 through approximately Day 112</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with clinically relevant changes from baseline in vital signs</measure>
    <time_frame>Day 1 through approximately Day 112</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with dose limiting adverse events</measure>
    <time_frame>Day 1 through approximately Day 112</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the number of specific B cells (subset) over time following single and multiple doses of PF-06835375</measure>
    <time_frame>Day 1 through approximately Day 112</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the number of specific T cells (subset) over time following single and multiple doses of PF-06835375</measure>
    <time_frame>Day 1 through approximately Day 112</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with anti-drug antibodies (ADA) to PF-06835375</measure>
    <time_frame>Day 1 through approximately Day 112</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-t)] of PF-06835375</measure>
    <time_frame>Day 1 through approximately Day 112</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) of PF-06835375</measure>
    <time_frame>Day 1 through approximately Day 112</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with neutralizing antibodies to PF-06835375</measure>
    <time_frame>Day 1 through approximately Day 112</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Clearance (CL) of PF-06835375</measure>
    <time_frame>Day 1 through approximately Day 112</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - âˆž)] of PF-06835375</measure>
    <time_frame>Day 1 through approximately Day 112</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of PF-06835375</measure>
    <time_frame>Day 1 through approximately Day 112</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Decay Half-Life of PF-06835375</measure>
    <time_frame>Day 1 to approximately Day 112</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-06835375</measure>
    <time_frame>Day 1 through approximately Day 112</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of Distribution at Steady State (Vss) of PF-06835375</measure>
    <time_frame>Day 1 through approximately Day 112</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCtau of PF-06835375 (dose normalized)</measure>
    <time_frame>Day 1 through approximately Day 112</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Concentration (Cav) of PF-06835375</measure>
    <time_frame>Day 1 through approximately Day 112</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean residence of time for PF-06835375</measure>
    <time_frame>Day 1 though approximately Day 112</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) dose normalized of PF-06835375</measure>
    <time_frame>Day 1 through approximately Day 112</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bioavailability of PF-06835375 subcutaneous doses compared to intravenous doses of PF-06835375</measure>
    <time_frame>Day 1 through approximately Day 112</time_frame>
  </secondary_outcome>
  <number_of_arms>14</number_of_arms>
  <enrollment type="Anticipated">112</enrollment>
  <condition>Systemic Lupus Erythematosus</condition>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Part A, Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive a single dose of PF-06835375 or placebo on Day 1 via intravenous administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A, Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive a single dose of PF-06835375 or placebo on Day 1 via intravenous administration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A, Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive a single dose of PF-06835375 or placebo on Day 1 via intravenous administration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A, Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive a single dose of PF-06835375 or placebo on Day 1 via intravenous administration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A, Cohort 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive a single dose of PF-06835375 or placebo on Day 1 via intravenous administration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A, Cohort 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive a single dose of PF-06835375 or placebo on Day 1 via intravenous administration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A, Cohort 7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive a single dose of PF-06835375 or placebo on Day 1 via intravenous administration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A, Cohort 8</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive a single dose of PF-06835375 or placebo on Day 1 via intravenous administration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B, Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive two doses of PF-06835375 or placebo on Day 1 and Day 29 via subcutaneous or intravenous administration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B, Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive two doses of PF-06835375 or placebo on Day 1 and Day 29 via subcutaneous or intravenous administration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B, Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive two doses of PF-06835375 or placebo on Day 1 and Day 29 via subcutaneous or intravenous administration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B, Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive two doses of PF-06835375 or placebo on Day 1 and Day 29 via subcutaneous or intravenous administration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B, Cohort 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive two doses of PF-06835375 or placebo on Day 1 and Day 29 via subcutaneous or intravenous administration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B, cohort 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive two doses of PF-06835375 or placebo on Day 1 and Day 29 via subcutaneous or intravenous administration.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-06835375</intervention_name>
    <description>Intravenous (IV) or subcutaneous (SC) administration. Subjects will receive one or two doses. Doses will be ascending and determined by emerging data.</description>
    <arm_group_label>Part A, Cohort 1</arm_group_label>
    <arm_group_label>Part A, Cohort 2</arm_group_label>
    <arm_group_label>Part A, Cohort 3</arm_group_label>
    <arm_group_label>Part A, Cohort 4</arm_group_label>
    <arm_group_label>Part A, Cohort 5</arm_group_label>
    <arm_group_label>Part A, Cohort 6</arm_group_label>
    <arm_group_label>Part A, Cohort 7</arm_group_label>
    <arm_group_label>Part A, Cohort 8</arm_group_label>
    <arm_group_label>Part B, Cohort 1</arm_group_label>
    <arm_group_label>Part B, Cohort 2</arm_group_label>
    <arm_group_label>Part B, Cohort 3</arm_group_label>
    <arm_group_label>Part B, Cohort 4</arm_group_label>
    <arm_group_label>Part B, Cohort 5</arm_group_label>
    <arm_group_label>Part B, cohort 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo for PF-06835375 IV or SC. Subjects will receive one or two doses.</description>
    <arm_group_label>Part A, Cohort 1</arm_group_label>
    <arm_group_label>Part A, Cohort 2</arm_group_label>
    <arm_group_label>Part A, Cohort 3</arm_group_label>
    <arm_group_label>Part A, Cohort 4</arm_group_label>
    <arm_group_label>Part A, Cohort 5</arm_group_label>
    <arm_group_label>Part A, Cohort 6</arm_group_label>
    <arm_group_label>Part A, Cohort 7</arm_group_label>
    <arm_group_label>Part A, Cohort 8</arm_group_label>
    <arm_group_label>Part B, Cohort 1</arm_group_label>
    <arm_group_label>Part B, Cohort 2</arm_group_label>
    <arm_group_label>Part B, Cohort 3</arm_group_label>
    <arm_group_label>Part B, Cohort 4</arm_group_label>
    <arm_group_label>Part B, Cohort 5</arm_group_label>
    <arm_group_label>Part B, cohort 6</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with Rheumatoid Arthritis: confirmed diagnosis according to 2010 ACR/EULAR
             criteria with symptom duration at least 6 months and positive with Rheumatoid Factor
             and/or anti citrullinated peptide antibody

          -  Patients with Systemic Lupus Erythematosus: Confirmed diagnosis according to the SLICC
             Classification Criteria with symptom duration at least 6 months and at least one of
             the following: positive antinuclear antibody titer, positive anti-dsDNA, anti-Smith
             antibodies

        Exclusion Criteria:

          -  Active central nervous system manifestations, systemic vasculitis or
             pleuro/pericarditis

          -  Active lupus nephritis

          -  Treatment with B cell depleting agents within 52 weeks prior to screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
    <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Pinnacle Research Group, LLC</name>
      <address>
        <city>Anniston</city>
        <state>Alabama</state>
        <zip>36201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pinnacle Research Group, LLC</name>
      <address>
        <city>Anniston</city>
        <state>Alabama</state>
        <zip>36207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Wallace Rheumatic Studies Center</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Prive aftercare</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Omega Research Maitland</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32810</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Altoona Center for Clinical Research</name>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <zip>16635</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Metroplex Clinical Research Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=C1131001&amp;StudyName=A+Phase+1%2C+Randomized%2C+Multi-center%2C+Double-blind%2C+Sponsor+Open%2C+Placebo-controlled%2C+Single+And+Multiple+Dose-escalation+Study+To+Evaluate+The+Safety%2C+Tolerability%2C+Pharmacokinetics+And+Pharmacodynamics+Of+Pf-06835375+In+Subjects+With+Seropositive+Systemic+Lupus+Erythematosus+Or+Rheumatoid+Arthritis</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 3, 2017</study_first_submitted>
  <study_first_submitted_qc>November 3, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 7, 2017</study_first_posted>
  <last_update_submitted>May 17, 2018</last_update_submitted>
  <last_update_submitted_qc>May 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

